These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26462439)

  • 21. [The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
    Gunlusoy B; Arslan M; Vardar E; Degirmenci T; Kara C; Ceylan Y; Kozacıoğlu Z
    Actas Urol Esp; 2012 Oct; 36(9):515-20. PubMed ID: 22819345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
    Ecke TH; Bartel P; Koch S; Ruttloff J; Theissig F
    Oncol Rep; 2006 Dec; 16(6):1381-8. PubMed ID: 17089065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
    Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
    Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes.
    Ichioka D; Miyazaki J; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Nishiyama H
    Jpn J Clin Oncol; 2015 Sep; 45(9):867-73. PubMed ID: 26056328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant Chemotherapy With Gemcitabine Plus Cisplatin for Kidney Transplant Patients With Locally Advanced Transitional Cell Carcinoma: A Single-center Experience.
    Wang ZP; Wang WY; Zhu YC; Xiao J; Lin J; Guo YW; Tian Y
    Transplant Proc; 2016; 48(6):2076-9. PubMed ID: 27569947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
    Kanai K; Kikuchi E; Ohigashi T; Miyajima A; Nakagawa K; Nakashima J; Oya M
    Int J Clin Oncol; 2008 Dec; 13(6):510-4. PubMed ID: 19093178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
    Schinzari G; Monterisi S; Pierconti F; Nazzicone G; Marandino L; Orlandi A; Racioppi M; Cassano A; Bassi P; Barone C; Rossi E
    Anticancer Res; 2017 Nov; 37(11):6453-6458. PubMed ID: 29061832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
    Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N;
    Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
    Meleis L; Moore R; Inman BA; Harrison MR
    J Oncol Pharm Pract; 2020 Mar; 26(2):330-337. PubMed ID: 31081469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
    Linardou H; Aravantinos G; Efstathiou E; Kalofonos C; Anagnostopoulos A; Deliveliotis C; Bafaloukos D; Athanasios Dimopoulos M; Bamias A;
    Urology; 2004 Sep; 64(3):479-84. PubMed ID: 15351574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.
    Adamo V; Magno C; Spitaleri G; Garipoli C; Maisano C; Alafaci E; Adamo B; Rossello R; Scandurra G; Scimone A
    Oncology; 2005; 69(5):391-8. PubMed ID: 16319510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
    Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R
    J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy.
    Türkölmez K; Bedük Y; Baltaci S; Göğüş C; Göğüş O
    Eur Urol; 2003 Dec; 44(6):682-6. PubMed ID: 14644120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.
    Matsubara N; Mukai H; Naito Y; Nezu M; Itoh K
    Asia Pac J Clin Oncol; 2013 Dec; 9(4):310-7. PubMed ID: 23127231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.
    Hussain SA; Stocken DD; Riley P; Palmer DH; Peake DR; Geh JI; Spooner D; James ND
    Br J Cancer; 2004 Aug; 91(5):844-9. PubMed ID: 15292922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
    Rose TL; Harrison MR; Deal AM; Ramalingam S; Whang YE; Brower B; Dunn M; Osterman CK; Heiling HM; Bjurlin MA; Smith AB; Nielsen ME; Tan HJ; Wallen E; Woods ME; George D; Zhang T; Drier A; Kim WY; Milowsky MI
    J Clin Oncol; 2021 Oct; 39(28):3140-3148. PubMed ID: 34428076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer.
    Tinker A; Winquist E; Canil C; Moore M; Murray RN; Chi KN
    Am J Clin Oncol; 2006 Feb; 29(1):3-7. PubMed ID: 16462494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patients.
    Chau C; Wheater M; Geldart T; Crabb SJ
    Eur J Cancer Care (Engl); 2015 Mar; 24(2):155-62. PubMed ID: 25620269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
    Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.